Immunogenicity and Safety of the Sanofi Pasteur's DTacP-IPV//PRP-T Combined Vaccine (PENTAXIM) Versus Sanofi Pasteur's DTacP-IPV Combined Vaccine (TETRAXIM) Given Simultaneously at Separate Sites With PRP-T Conjugate Vaccine (ACTHIB) as a Three-dose Primary Vaccination at 2, 4 and 6 Months of Age in South Korean Infants.

Trial Profile

Immunogenicity and Safety of the Sanofi Pasteur's DTacP-IPV//PRP-T Combined Vaccine (PENTAXIM) Versus Sanofi Pasteur's DTacP-IPV Combined Vaccine (TETRAXIM) Given Simultaneously at Separate Sites With PRP-T Conjugate Vaccine (ACTHIB) as a Three-dose Primary Vaccination at 2, 4 and 6 Months of Age in South Korean Infants.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs DTaP poliovirus vaccine; Hib vaccine conjugate; Hib-DTaP-poliovirus vaccine
  • Indications Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors Sanofi
  • Most Recent Events

    • 01 Sep 2016 Results published in the Journal of Korean Medical Science
    • 16 Apr 2012 Actual patient number is 370 according to ClinicalTrials.gov.
    • 16 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top